BioSpace5h
Amgen, Kyowa Kirin’s Rocatinlimab Picks Up Steam With Late-Stage Atopic Dermatitis Win
In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...
Clinical Trials Arena on MSN1d
Amgen and Kyowa Kirin’s rocatinlimab trial for atopic dermatitis meets endpoints
All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.
Fierce Biotech1d
Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...
European Medical Journal1h
Nemolizumab in Moderate-to-Severe Atopic Dermatitis: Long-Term Safety and Efficacy and New Biomarker Insights
Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...
Zacks Investment Research on MSN1d
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
Amgen AMGN announced positive results from two clinical studies, IGNITE and SHUTTLE, which are part of the phase III ROCKET ...
Pharmabiz11h
Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis
Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...
Amgen, Kyowa announces new results from ongoing ROCKET Phase 3 study
Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...
Medscape1d
Analysis Takes a Deep Dive Into Robust Response to Delgocitinib for Chronic Hand Eczema
Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...
The Pharma Letter1d
Amgen and Kyowa Kirin announce rocatinlimab Phase III success
US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...
Amgen And Kyowa Kirin Provide Top-line Results From Rocatinlimab Phase 3 Ignite Study In Adults With Moderate To Severe Atopic Dermatitis
Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...